Photodynamic therapy reduces SRF in symptomatic choroidal nevus

Article

Photodynamic therapy reduces subretinal fluid (SRF) in patients with symptomatic choroidal nevus with serous macular detachment.

Photodynamic therapy reduces subretinal fluid (SRF) in patients with symptomatic choroidal nevus with serous macular detachment, according to a study featured in the journal Retina.

Dr Jose García-Arumí et al., Ophthalmology Department, Institute of Ocular Microsurgery, Barcelona, Spain, included 17 patients in the study. The retrospective review involved the evaluation of the medical records of all participants who underwent photodynamic therapy (PDT) for symptomatic choroidal nevus with SRF.

Mean final visual acuity improved to 20/60, subretinal fluid was reduced in all eyes and wasn't present at all in nine eyes. Out of the nine patients who didn't have subretinal fluid, 2 patients showed a recurrence.

The mean final tumour thickness increased to 1.24 mm after a mean follow-up time of 22.47 months. Tumour thickness increased in three eyes, stayed the same in 13 eyes and one lesion in one eye was reduced to a flat, chorioretinal scar.

Photodynamic therapy is an efficient treatment option for reducing SRF in symptomatic choroidal nevus with serous macular detachment. However, melanoma was found in 18% of patients, suggesting that PDT does not control tumours.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.